BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

A Randomized, Placebo-Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina

(2012) B R Chaitman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease

(2012) Tony W. Ho et al.   HEADACHE

Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine

(2012) Guanglin Luo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

(2011) David J Hewitt et al.   CEPHALALGIA

Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus

(2010) O. Summ et al.   BRAIN

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

(2010) Hans-Christoph Diener et al.   CEPHALALGIA

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET